Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

RDY stock hub

Dr. Reddy's Laboratories Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RDYis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

11.4B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

RDY

In the news

Latest news · RDY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E22.8

P25 12.6P50 18.3P75 33.7

Trailing P/E18.1

P25 15P50 23.3P75 38.5

ROE16.1

P25 -106.6P50 -46.9P75 -3.1

ROIC14.4

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RDY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

272

Groups with data

Currency

INR

Showing 272 of 272 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001135951
Company name	Dr. Reddy's Laboratories Limited
Country	India
Country code	US
Cusip	256135203
Employees	27,811
Employees Change	763%
Employees Change Percent	2.82
Enterprise value	$11.3B
Exchange	NYSE
Financial currency	INR
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Isin	US2561352038
Last refreshed	2026-05-10
Market cap	$11.4B
Market cap category	Large-Cap
Price	$13.23
Price currency	USD
Rev Per Employee	138,387.5x
Sector	Healthcare
Sic	2834
Symbol	RDY
Website	https://www.drreddys.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.52%
EV Earnings	17.91x
EV Sales Forward	0.03x
EV/EBIT	15.25x
EV/EBITDA	11.95x
EV/FCF	29.06x
EV/Sales	2.93x
FCF yield	3.4%
Forward P/E	22.76x
P/B ratio	2.73x
P/E ratio	18.1x
P/S ratio	2.96x
PE Ratio10 Y	29.15x
PE Ratio3 Y	18.66x
PE Ratio5 Y	24.49x
PS Forward	0.03x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	19.22%
EBITDA Margin	24.52%
FCF margin	10.09%
Gross margin	55.18%
Gross Profit	$2.1B
Gross Profit Growth	3.35%
Gross Profit Growth Q	-4.58%
Gross Profit Growth3 Y	13.05%
Gross Profit Growth5 Y	13.68%
Net Income	$629.7M
Net Income Growth	5.42%
Net Income Growth Q	-14.4%
Net Income Growth Years	4%
Net Income Growth3 Y	15.9%
Net Income Growth5 Y	21.63%
Pretax Margin	21.07%
Profit Margin	16.36%
Profit Per Employee	$22,644
Profitable Years	16
ROA	7.96
Roa5y	9.82
ROCE	16.42
ROE	16.1
Roe5y	17.03
ROIC	14.38
Roic5y	19.14

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	5.29%
Cagr15y	4.76%
Cagr1y	-1.67%
Cagr20y	7.21%
Cagr3y	3.41%
Cagr5y	-0.9%
Div CAGR10	2.49%
Div CAGR3	-4.46%
Div CAGR5	5.03%
EPS Growth	5.58
EPS Growth Q	-14.29
EPS Growth Years	4
EPS Growth3 Y	15.85
EPS Growth5 Y	21.59
FCF Growth	237.35%
FCF Growth3 Y	0.76%
FCF Growth5 Y	14.5%
OCF Growth	75.53%
OCF Growth Q	64.77%
OCF Growth10 Y	4.09%
OCF Growth3 Y	9.31%
OCF Growth5 Y	18.52%
Revenue Growth	11.09x
Revenue Growth Q	4.41x
Revenue Growth Years	8x
Revenue Growth3 Y	13.38x
Revenue Growth5 Y	13.11x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.66
Assets	$6.3B
Cash	$919.1M
Current Assets	$3.2B
Current Liabilities	$1.7B
Debt	$753.8M
Debt EBITDA	$0.79
Debt Equity	$0.18
Debt FCF	$1.94
Equity	$4.2B
Interest Coverage	19.91
Liabilities	$2.1B
Long Term Assets	$3.1B
Long Term Liabilities	$406.1M
Net Cash	$165.3M
Net Cash By Market Cap	$1.45
Net Cash Growth	68.12%
Net Debt EBITDA	$-0.18
Net Debt Equity	$-0.04
Net Debt FCF	$-0.43
Tangible Book Value	$2.9B
Tangible Book Value Per Share	$3.44
WACC	5.78

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.88
Inventory Turnover	2.06
Net Working Capital	$1.3B
Quick ratio	1.18
Working Capital	$1.5B
Working Capital Turnover	$0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.15%
Dividend Growth	-11.54%
Dividend Growth Years	0%
Dividend per share	$0.07
Dividend Years	25
Dividend Yield	0.54%
Ex Div Date	2025-07-25
Last Dividend	$0.07
Payout Frequency	Annual
Payout Ratio	9.46%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	67.35%
1Y total return	-1.67%
200-day SMA	13.96
3Y total return	10.58%
50-day SMA	13.67
50-day SMA vs 200-day SMA	50under200
5Y total return	-4.42%
All Time High	16.89
All Time High Change	-21.68%
All Time High Date	2024-08-09
All Time Low	1
All Time Low Change	1,217.73%
All Time Low Date	2001-04-11
ATR	0.32
Beta	0.3
Ch YTD	-5.77
High	13.56
High52	16.17
High52 Date	2025-06-12
High52ch	-18.18%
Low	13.22
Low52	12.77
Low52 Date	2026-04-21
Low52ch	3.6%
Ma50ch	-3.23%
Premarket Change Percent	0.89
Premarket Price	$13.55
Premarket Volume	1,140
Price vs 200-day SMA	-5.26%
RSI	44.87
RSI Monthly	46.01
RSI Weekly	41.68
Sharpe ratio	-0.13x
Sortino ratio	0.06
Total Return	0.69%
Tr YTD	-5.77
Tr15y	100.79%
Tr1m	2.16%
Tr1w	-3.57%
Tr3m	-6.04%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$0.09
Earnings EPS Estimate Growth	-59.09
Earnings Revenue Estimate	866,120,000x
Earnings Revenue Estimate Growth	-13.04x
Operating Income	$739.5M
Operating Income Growth	-4.73
Operating Income Growth Q	-23.4
Operating Income Growth3 Y	10.35
Operating Income Growth5 Y	15.67
Operating margin	19.22
Price target	$16.9
Price Target Change	$27.74

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	599,497,266%
Float Percent	72.01%
Net Borrowing	59,803,761.9
Shares Insiders	26.74%
Shares Institutions	63.4%
Shares Out	832,568,190
Shares Qo Q	0%
Shares Yo Y	-0.15%
Short Ratio	5.6
Short Shares	3.09

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$384.4M
Average Volume	2,686,276.9x
Bv Per Share	4.98
CAPEX	$-294.4M
Ch10y	57.88
Ch15y	80.1
Ch1m	2.16
Ch1w	-3.57
Ch1y	-2.14
Ch20y	251.2
Ch3m	-6.04
Ch3y	8.84
Ch5y	-6.86
Ch6m	-1.71
Change	-1.49%
Change From Open	-2.43
Close	13.43
Days Gap	0.97
Depreciation Amortization	194,163,656.9
Dollar Volume	33,566,335.7
Earnings Date	2026-05-12
Earnings Time	bmo
EBIT	$739.5M
EBITDA	$943.6M
EPS	$0.76
F Score	4
FCF	$388.2M
FCF EV Yield	3.44x
FCF Per Share	$0.47
Financing CF	-68,097,317
Fiscal Year End	March
Founded	1,984
Goodwill	131,426,365.4
Graham Number	8.9323
Graham Upside	-32.48
Income Tax	$186.4M
Investing CF	-582,338,340
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-01-20
Last Report Date	2025-12-31
Last Split Date	2024-11-05
Last Split Type	Forward
Last10k Filing Date	2025-06-06
Lynch Fair Value	$15.81
Lynch Upside	19.48
Ma150	13.86
Ma150ch	-4.54%
Ma20	13.37
Ma20ch	-1.08%
Net CF	62,599,674
Next Earnings Date	2026-05-12
Open	13.56
Optionable	Yes
P FCF Ratio	29.37
P OCF Ratio	16.23
Payment Date	2025-08-06
Position In Range	2.94
Post Close	13.23
Postmarket Change Percent	0.91
Postmarket Price	$13.35
Ppne	1,223,652,535
Pre Close	13.43
Price Date	2026-05-08
Price EBITDA	$12.08
Ptbv Ratio	3.98
Relative Volume	0.94x
Revenue	3,848,694,754x
SBC By Revenue	0.1x
Share Based Comp	3,839,447
Tax By Revenue	4.84x
Tax Rate	22.98%
Tr20y	302.03%
Tr6m	-1.71%
Volume	2,537,138
Z Score	5.49

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

RDY dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.5%

$0.07 annual per share

Payout ratio

+9.5%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+5.0%

0 consecutive years of growth

Total shareholder yield

+0.7%

Next ex-dividend date: 2025-07-25

Performance

RDY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RDY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+63.4%

Float: +72.0% of shares outstanding

Insider ownership

+26.7%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RDY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.9

Neutral momentum band

Price vs 200-day MA

-5.3%

50/200-day relationship not available

Beta (5Y)

0.30

Less volatile than the market

Sharpe ratio

-0.13

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RDY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RDY stock rating?

Dr. Reddy's Laboratories Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RDY analysis?

The full report lives at /stocks/RDY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RDY?

The latest report frames RDY around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RDY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.